FDA staff question evidence for seven peptides, setting clash with Kennedy

FDA staff reviewers have said there is little human evidence to justify letting compounding pharmacies make seven popular peptides, setting up a fight with Health Secretary Robert F. Kennedy Jr. over how far the agency should reopen access to unapproved drugs.

The Pharmacy Compounding Advisory Committee is scheduled to meet July 23-24, 2026, at the White Oak Campus in Silver Spring, Maryland. FDA says the committee’s recommendations are non-binding, although the agency generally follows them, making the two-day session a key test of how aggressively the agency will police compounded medicines.

The review is split across both days. On July 23, the panel is set to discuss BPC-157, KPV, TB-500 and MOTS-c. On July 24, members will turn to emideltide, also called delta sleeping inducing peptide or DSIP, semax and epitalon. The FDA has posted the peptides with claimed uses ranging from ulcerative colitis and wound healing to obesity, osteoporosis, opioid withdrawal, chronic insomnia, cerebral ischemia, migraines and chronic pain.

Under the agency’s 503A framework, state-licensed physicians and pharmacists may compound from bulk drug substances only under specific conditions, including when a substance appears on FDA’s 503A bulks list. That list is meant to reserve compounding for situations where a drug is needed for individual patients and where the substance has cleared the agency’s bulks review. FDA staff argued the available human studies for the seven peptides do not provide enough support on safety or effectiveness to meet that standard.

The stakes are not limited to clinical evidence. If access expands, compounding pharmacies, peptide suppliers and clinics that market these products stand to gain from a larger legal market. Patients could also face the familiar risks that come with compounded drugs: variable quality, weaker oversight and exposure to substances that have not been backed by the kind of human data normally required for approved medicines.

The agency is already drawing a harder line elsewhere. In April 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, saying it found no clinical need for outsourcing facilities to compound those drugs from bulk substances. FDA invited comments on that proposal through June 29, 2026, underscoring a broader posture of tightening access when approved drugs already exist.

Kennedy widened the political clash in February 2026, saying FDA acted illegally in 2023 when it classified 19 peptides as too unsafe for compounders. Former FDA officials have said that 2023 decision was backed by numerous documented safety concerns, and that the agency must weigh both safety and effectiveness before allowing bulk compounding.

The panel itself has become part of the debate. The newly appointed committee includes more doctors and pharmacists with ties to peptide prescribing, production or promotion than earlier panels that leaned more heavily toward academics from universities such as Duke, Harvard and Johns Hopkins. Some of the peptides under review, including BPC-157 and TB-500, are also discussed in sports circles and are considered doping substances by international sports authorities.